Sugar-Based Excipients Research Business Report 2025: Global Market to Reach $1.4 Billion by 2030 - Rising Demand for Orally Disintegrating Tablets (ODTs) Expands Opportunities
Fueled by advancements in drug delivery and a rising demand for orally disintegrating and chewable tablets, sugar-based excipients like sucrose, glucose, and lactose are crucial in pharmaceuticals, especially in pediatric and geriatric formulations. Key regions include North America, Europe, and Asia-Pacific, with major players like Archer Daniels Midland and BASF SE driving innovation.
Sugar-Based Excipients Market
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Sugar-Based Excipients - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Sugar-Based Excipients was valued at US$1.1 Billion in 2024 and is projected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Sugar-Based Excipients market.
Sugar-based excipients play a vital role in pharmaceutical formulations, where they are used as fillers, binders, and sweeteners to improve the taste and stability of medicines. These excipients are particularly valuable in pediatric and geriatric formulations, where the palatability of medications is a key factor in compliance. Sucrose, glucose, and lactose are among the most commonly used sugar-based excipients, providing sweetness and aiding in the proper release of active ingredients. The growing demand for orally disintegrating tablets (ODTs) and chewable tablets has further expanded the use of sugar-based excipients, as these dosage forms rely on excipients that enhance mouthfeel and dissolution.
What Drives Growth in the Sugar-Based Excipients Market?The growth in the Sugar-Based Excipients market is driven by several factors, including the increasing demand for orally disintegrating tablets and chewable formulations, as well as advancements in drug delivery systems. The rising prevalence of chronic diseases and the growing pediatric and geriatric populations are boosting the demand for easy-to-administer dosage forms, where sugar-based excipients play a crucial role.
Additionally, the growing nutraceuticals market is expanding the use of sugar-based excipients in dietary supplements. As pharmaceutical companies continue to innovate in taste-masking and multifunctional excipients, the market is poised for continued growth.What Technological Advancements Are Shaping the Sugar-Based Excipients Market?Technological innovations in drug delivery systems have led to the development of more effective sugar-based excipients. Manufacturers are focusing on creating excipients that not only enhance the taste of medications but also improve drug bioavailability and stability. The advent of multifunctional excipients has enabled pharmaceutical companies to reduce the number of components in formulations, simplifying production processes and improving product performance.
Additionally, advancements in taste-masking technologies are allowing sugar-based excipients to be used in bitter-tasting drugs, making them more palatable for patients. This is particularly important in the development of pediatric and geriatric medicines, where ease of consumption is critical.Which Segments Are Leading the Sugar-Based Excipients Market?Common product types include sucrose, lactose, and mannitol, with sucrose being the most widely used due to its sweetness and solubility. In terms of form, sugar-based excipients are available as powders, granules, and syrups, with powders being the most common form in tablet formulations. The pharmaceutical industry is the largest end-user of sugar-based excipients, followed by nutraceuticals and food supplement
Geographically, North America and Europe dominate the market due to their robust pharmaceutical industries, while emerging markets in Asia-Pacific are expected to grow due to increased drug production and rising healthcare spending.Report ScopeKey Insights:
Market Growth: Understand the significant growth trajectory of the Actual Sugars segment, which is expected to reach US$818.5 Million by 2030 with a CAGR of a 4.8%. The Sugar Alcohols segment is also set to grow at 4.1% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $283.6 Million in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $292.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as Archer Daniels Midland Company, Ashland, Inc., Associated British Foods PLC, BASF SE, Cargill, Inc. and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Segments:
Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners)
Type (Powder / Granule, Crystal, Syrup, Direct Compression Sugars)
Formulation (Oral, Topical, Parenteral, Other Formulations)
What's Included in This Edition:
Tariff-adjusted market forecasts by region and segment
Analysis of cost and supply chain implications by sourcing and trade exposure
Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
Finalized tariff impacts and new trade agreement effects
Updated projections reflecting global sourcing and cost shifts
Expanded country-specific coverage across the industry
Key Attributes:
Report Attribute
Details
No. of Pages
313
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$1.1 Billion
Forecasted Market Value (USD) by 2030
$1.4 Billion
Compound Annual Growth Rate
4.4%
Regions Covered
Global
Key Topics Covered: MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Sugar-Based Excipients - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
Increasing Use of Sugar-Based Excipients in Pharmaceuticals Spurs Market Growth
Technological Advancements in Drug Delivery Systems Strengthen the Business Case for Sugar-Based Excipients
Rising Demand for Orally Disintegrating Tablets (ODTs) Expands Addressable Market Opportunity
Focus on Improving Palatability of Medications Drives Adoption of Sugar-Based Excipients
Growing Popularity of Natural and Non-Toxic Excipients in Pharmaceuticals Propels Market Demand
Focus on Pediatric and Geriatric Formulations Reinforces Demand for Sugar-Based Excipients
Rising Use of Sugar Alcohols as Excipient Alternatives Throws Spotlight on Market Trends
Emergence of Biopharmaceuticals Propels the Need for Innovative Sugar-Based Excipients
Increased Focus on Functional Excipients That Improve Drug Stability Drives Market Growth
Challenges in Regulatory Stringency and Compliance Create Opportunities for High-Quality Sugar-Based Excipients
Rising Demand for Taste-Masking Excipients Expands Applications in Bitter Drug Formulations
Growing Adoption of Sugar-Based Excipients in Nutraceuticals Sustains Market Growth
FOCUS ON SELECT PLAYERS -Some of the 22 companies featured in this Sugar-Based Excipients market report
Archer Daniels Midland Company
Ashland, Inc.
Associated British Foods PLC
BASF SE
Cargill, Inc.
Colorcon, Inc.
DFE Pharma GmbH & Co. KG
FMC Corporation
Molkerei MEGGLE Wasserburg GmbH & Co. KG
Roquette Freres S.A.
The Lubrizol Corporation
For more information about this report visit https://www.researchandmarkets.com/r/mrbdn0
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Sugar-Based Excipients Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Hello Group Inc. Announces Unaudited Financial Results for the First Quarter of 2025
BEIJING, June 5, 2025 /PRNewswire/ -- Hello Group Inc. (NASDAQ: MOMO) ("Hello Group" or the "Company"), a leading player in Asia's online social and entertainment space, today announced its unaudited financial results for the first quarter of 2025. First Quarter of 2025 Highlights Net revenues decreased by 1.5% year over year to RMB2,520.8 million (US$347.4 million*) in the first quarter of 2025. Net revenues from overseas increased by 71.9% year over year to RMB414.6 million (US$57.1 million) in the first quarter of 2025. Net income attributable to Hello Group Inc. increased to RMB358.0 million (US$49.3 million) in the first quarter of 2025, from RMB5.2 million in the same period of 2024. Non-GAAP net income attributable to Hello Group Inc. (note 1) increased to RMB403.8 million (US$55.6 million) in the first quarter of 2025, from RMB59.9 million in the same period of 2024. Diluted net income per American Depositary Share ("ADS") was RMB2.07 (US$0.29) in the first quarter of 2025, compared to RMB0.03 in the same period of 2024. Non-GAAP diluted net income per ADS (note 1) was RMB2.34 (US$0.32) in the first quarter of 2025, compared to RMB0.31 in the same period of 2024. Monthly Active Users ("MAU") on Tantan app were 10.7 million in March 2025, compared to 13.7 million in March 2024. For the Momo app total paying users was 4.2 million for the first quarter of 2025, compared to 7.1 million for the same period last year. Tantan had 0.8 million paying users for the first quarter of 2025 compared to 1.1 million from the year ago period. * This press release contains translations of certain Renminbi amounts into U.S. dollars at specified rate solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars, in this press release, were made at a rate of RMB7.2567 to US$1.00, the effective noon buying rate for March 31, 2025 as set forth in the H.10 statistical release of the Federal Reserve Board. "Q1 marked a strong start to 2025," commented Yan Tang, Chairman and CEO of Hello Group. "Our mainland PRC businesses continue to deliver solid profits, thanks to our ongoing efforts in cost reduction and efficiency improvement, as well as gradual stabilization of external factors. Meanwhile, our overseas business growth has accelerated, driven by further localization of existing products and the initial monetization of new apps. We expect the overseas products to make an increasingly meaningful contribution to the Group's financials in the coming quarters." First Quarter of 2025 Financial Results Net revenues Total net revenues were RMB2,520.8 million (US$347.4 million) in the first quarter of 2025, a decrease of 1.5% from RMB2,560.4 million in the first quarter of 2024. Starting from the first quarter of 2025, the Company combined the live video service and value-added services lines, which are now collectively referred to as value-added services. This change reflects the increasing convergence of the two business lines in terms of user mentality and product format. The combined reporting more accurately reflects user behavior and spending across the Company's social entertainment ecosystem. Additionally, the Company consolidated mobile marketing services, mobile games and other services, which are now collectively reported under "other services." Value-added service revenues mainly include virtual gift revenues from various audio, video and text- based scenarios, and membership subscription revenues. Total value-added service revenues were RMB2,489.9 million (US$343.1 million) in the first quarter of 2025, a decrease of 1.7% from RMB2,532.9 million during the same period of 2024. The decrease was primarily due to a soft consumer sentiment among top users in the current macro environment of Momo app, and to a lesser extent, the decline in Tantan's paying users which was in turn due to the decline in user base. The decrease was partially offset by the rapid revenue growth from our overseas apps, driven by the strong performance of the relatively established brand--Soulchill and the monetization of a collection of new apps. Other services revenues were RMB30.9 million (US$4.3 million) in the first quarter of 2025, compared to RMB27.5 million during the same period of 2024. Net revenues from Chinese mainland decreased from RMB2,319.2 million in the first quarter of 2024 to RMB2,106.2 million (US$290.2 million) in the first quarter of 2025, primarily due to the decrease in net revenues from Momo app and Tantan app. Net revenues from overseas increased from RMB241.2 million in the first quarter of 2024 to RMB414.6 million (US$57.1 million) in the first quarter of 2025, driven by the growth of Souchill and incremental revenue from emerging brands. Cost and expenses Cost and expenses were RMB2,234.5 million (US$307.9 million) in the first quarter of 2025, an increase of 5.4% from RMB2,120.0 million in the first quarter of 2024. The increase was primarily attributable to: (a) an increase in revenue sharing with virtual gift recipients for overseas apps, which was partially offset by a decrease in revenue sharing with broadcasters on Momo apps; and (b) an increase in sales and marketing expenses related to the promotion of overseas apps, partially offset by a decrease in Tantan's marketing and promotional expense due to our continuous initiatives to control cost and optimize Tantan's channel marketing strategy. Non-GAAP cost and expenses (note 1) were RMB2,188.8 million (US$301.6 million) in the first quarter of 2025, compared to RMB2,065.3 million during the same period of 2024. Income from operations Income from operations was RMB299.5 million (US$41.3 million) in the first quarter of 2025, compared to RMB460.3 million during the same period of 2024. Non-GAAP income from operations (note 1) was RMB345.3 million (US$47.6 million) in the first quarter of 2025, compared to RMB515.0 million during the same period of 2024. Income tax expenses Income tax expenses were RMB70.4 million (US$9.7 million) in the first quarter of 2025, compared to RMB557.6 million in the first quarter of 2024. The decrease in income tax expenses was primarily due to the accrual in the first quarter of 2024 of withholding income tax of RMB448.6 million associated with historical undistributed earnings generated by our wholly-foreign owned enterprise. Net income Net income was RMB358.5 million (US$49.4 million) in the first quarter of 2025, compared to RMB5.2 million during the same period of 2024. Non-GAAP net income (note 1) was RMB404.3 million (US$55.7 million) in the first quarter of 2025, compared to RMB59.9 million during the same period of 2024. Net income attributable to Hello Group Inc. Net income attributable to Hello Group Inc. was RMB358.0 million (US$49.3 million) in the first quarter of 2025, compared to RMB5.2 million during the same period of 2024. Non-GAAP net income (note 1) attributable to Hello Group Inc. was RMB403.8 million (US$55.6 million) in the first quarter of 2025, compared to RMB59.9 million during the same period of 2024. Net income per ADS Diluted net income per ADS was RMB2.07 (US$0.29) in the first quarter of 2025, compared to RMB0.03 in the first quarter of 2024. Non-GAAP diluted net income per ADS (note 1) was RMB2.34 (US$0.32) in the first quarter of 2025, compared to RMB0.31 in the first quarter of 2024. Cash and cash flow As of March 31, 2025, the Company's cash, cash equivalents, short-term deposits, long-term deposits, short-term restricted cash and long-term restricted cash totaled RMB12,785.9 million (US$1,761.9 million), compared to RMB14,728.5 million as of December 31, 2024. Net cash provided by operating activities in the first quarter of 2025 was RMB239.7 million (US$33.0 million), compared to RMB400.2 million in the first quarter of 2024. Change in Segment Reporting Effective from the first quarter of 2025, the Company implemented the strategic decision to integrate the operations of Momo, Tantan, and QOOL into a unified business structure, and as a result, changed its segment disclosure from three operating segments to a single operating segment. This change reflects the Company's strategic focus and aligns with the financial information that the Company's chief operating decision maker currently receives and uses to allocate resources and assess performance of the Company. Prior period segment information has been retrospectively revised to conform to the current presentation. Recent Development Payment of a special cash dividend In March 2025, Hello Group's board of directors declared a special cash dividend in the amount of US$0.30 per ADS, or US$0.15 per ordinary share. The cash dividend was paid in April 2025 to shareholders of record at the close of business on April 11, 2025. The aggregate amount of cash dividends paid was US$47.9 million. Share repurchase program As of June, 5, 2025, the Company has repurchased 47.8 million ADSs for US$291.3 million on the open market under Share Repurchase Program announced on June 7, 2022 and amended on March 14, 2024 and March 12, 2025, at an average purchase price of US$6.07 per ADS. The remaining size of the program is USD $194.8 million. Business Outlook For the second quarter of 2025, the Company expects total net revenues to be between RMB2.57 billion to RMB2.67 billion, representing a decrease of 4.5% to 0.8% year over year. This forecast reflects the Company's current and preliminary views on the market and operational conditions, which are subject to change. Note 1: Non-GAAP measures To supplement our consolidated financial statements presented in accordance with U.S. generally accepted accounting principles ("GAAP"), we, Hello Group, use various non-GAAP financial measures that are adjusted from the most comparable GAAP results to exclude share-based compensation and amortization of intangible assets from business acquisitions, and such adjustments has no impact on income tax. Reconciliations of our non-GAAP financial measures to our U.S. GAAP financial measures are shown in tables at the end of this earnings release, which provide more details about the non-GAAP financial measures. Our non-GAAP financial information is provided as additional information to help investors compare business trends among different reporting periods on a consistent basis and to enhance investors' overall understanding of the historical and current financial performance of our continuing operations and our prospects for the future. Our non-GAAP financial information should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to the GAAP results. In addition, our calculation of the non-GAAP financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. Our non-GAAP information (including non-GAAP cost and operating expenses, income from operations, net income, net income attributable to Hello Group Inc., and diluted net income per ADS) is adjusted from the most comparable GAAP results to exclude share-based compensation and amortization of intangible assets from business acquisitions, and such adjustments has no impact on income tax. A limitation of using these non-GAAP financial measures is that share-based compensation and amortization of intangible assets from business acquisitions have been and will continue to be for the foreseeable future significant recurring expenses in our results of operations. We compensate for such limitation by providing reconciliations of our non-GAAP measures to our U.S. GAAP measures. Please see the reconciliation tables at the end of this earnings release. Conference Call Hello Group's management will host an earnings conference call on Thursday, June 5, 2025, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing / Hong Kong Time on June 5, 2025). Participants can register for the conference call by navigating to: Upon registration, each participant will receive details for the conference call, including dial-in numbers, conference call passcode and a unique access PIN. Please dial in 10 minutes before the call is scheduled to begin. A telephone replay of the call will be available after the conclusion of the conference call through June 12, 2025. The dial-in details for the replay are as follows: U.S. / Canada: 1-855-883-1031 Hong Kong: 800-930-639Passcode: 10047425 Additionally, a live and archived webcast of the conference call will be available on the Investor Relations section of Hello Group's website at About Hello Group Inc. We are a leading player in Asia's online social networking space. Through Momo, Tantan and other properties within our product portfolio, we enable users to discover new relationships, expand their social connections and build meaningful interactions. Momo is a mobile application that connects people and facilitates social interactions based on location, interests and a variety of online recreational activities. Tantan, which was added into our family of applications through acquisition in May 2018, is a leading social and dating application. Tantan is designed to help its users find and establish romantic connections as well as meet interesting people. Starting from 2019, we have incubated a number of other new apps, such as Hertz, Soulchill, and Duidui, which target more niche markets and more selective demographics. For investor and media inquiries, please contact: Hello Group Inc. Investor RelationsPhone: +86-10-5731-0538Email: ir@ Christensen In ChinaMs. Xiaoyan SuPhone: +86-10-5900-1548E-mail: In U.S. Ms. Linda BergkampPhone: +1-480-614-3004Email: Safe Harbor Statement This news release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include but are not limited to our management quotes, our financial outlook for the second quarter of 2025, as well as the amount of, timing, methods and funding sources for repurchases of our shares under the share repurchase program. Our forward-looking statements are not historical facts but instead represent only our belief regarding expected results and events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and other circumstances may differ, possibly materially, from the anticipated results and events indicated in these forward-looking statements. Announced results for the first quarter of 2025 are preliminary, unaudited and subject to audit adjustment. In addition, we may not meet our financial outlook for the second quarter of 2025 and may be unable to grow our business in the manner planned. We may also modify our strategy for growth. Moreover, there are other risks and uncertainties that could cause our actual results to differ from what we currently anticipate, including those relating to our ability to retain and grow our user base, our ability to attract and retain sufficiently trained professionals to support our operations, our ability to anticipate and develop new services and enhance existing services to meet the demand of our users or customers, the market price of the Company's stock prevailing from time to time, the nature of other investment opportunities presented to the Company from time to time, the Company's cash flows from operations, general economic conditions, and other factors. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations, and prospects, please see our filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such information speaks only as of the date of this release. Hello Group Inc. Unaudited Condensed Consolidated Statement of Operations (All amounts in thousands, except share and per share data)Three months Ended March 31202420252025RMBRMBUS$ Net revenues(i):Value-added service 2,532,9172,489,902343,118 Other services 27,50330,9334,262 Total net revenues 2,560,4202,520,835347,380 Cost and expenses:Cost of revenues (1,503,008)(1,569,074)(216,224) Research and development (192,191)(195,769)(26,978) Sales and marketing (293,431)(329,178)(45,362) General and administrative (131,381)(140,511)(19,363) Total cost and expenses (2,120,011)(2,234,532)(307,927) Other operating income, net 19,90613,1821,817 Income from operations 460,315299,48541,270 Interest income 121,107120,33816,583 Interest expense (23,698)(30,659)(4,225) Other gain or loss, net (9,245)-- Income before income tax and share of income on equity methodinvestments 548,479389,16453,628 Income tax expenses (557,613)(70,406)(9,702) (Loss) income before share of income on equity methodinvestments (9,134)318,75843,926 Share of income on equity method investments 14,31839,7315,475 Net income 5,184358,48949,401 Less: net income attributable to non-controlling interest -49568 Net income attributable to the shareholders of Hello Group Inc. 5,184357,99449,333 Net income per share attributable to ordinary shareholdersBasic 0.011.050.15 Diluted 0.011.040.14 Weighted average shares used in calculating net income per ordinaryshareBasic 374,650,649339,405,347339,405,347 Diluted 389,278,806345,905,274345,905,274 (i) The following table presents revenues by geographic area based on the addresses of our customers of our users: Three months Ended March 31 202420252025RMBRMBUS$ Chinese mainland 2,319,2232,106,233290,247 Overseas 241,197414,60257,133 Total 2,560,4202,520,835347,380 Hello Group Inc. Unaudited Condensed Consolidated Statement of Comprehensive Income (All amounts in thousands, except share and per share data) Three monthsEnded March 31 202420252025 RMBRMBUS$Net income 5,184358,48949,401Other comprehensive income (loss), net of tax: Foreign currency translation adjustment 54,894(43,338)(5,972)Comprehensive income 60,078315,15143,429Less: comprehensive income (loss) attributed to the non-controllinginterest 3,084(599)(83)Comprehensive income attributable to Hello Group Inc. 56,994315,75043,512 Hello Group Inc. Unaudited Condensed Consolidated Balance Sheets (All amounts in thousands, except share and per share data)December 31March 31March 31202420252025 RMB RMBUS$ AssetsCurrent assetsCash and cash equivalents 4,122,6595,381,833741,636 Short-term deposits 2,026,245762,835105,121 Restricted cash 4,566,4772,637,531363,461 Accounts receivable, net of allowance for credit losses of RMB12,433 andRMB17,427 as of December 31, 2024 and March 31, 2025, respectively 192,317222,21330,622 Prepaid expenses and other current assets 1,104,1721,099,969151,580 Total current assets 12,011,87010,104,3811,392,420 Long-term deposits 3,059,8603,051,340420,486 Long-term restricted cash 953,285952,391131,243 Right-of-use assets, net 252,169216,05429,773 Property and equipment, net 897,036916,423126,286 Intangible assets, net 86,661191,92726,448 Rental deposits 13,28013,3871,845 Long-term investments 825,533863,342118,972 Other non-current assets 110,960133,42018,386 Deferred tax assets 36,06635,7264,923 Goodwill 136,250249,41234,370 Total assets 18,382,97016,727,8032,305,152 Liabilities and equityCurrent liabilitiesAccounts payable 615,254619,82485,414 Deferred revenue 427,702437,35160,269 Accrued expenses and other current liabilities 704,410652,23489,880 Lease liabilities due within one year 141,971127,76517,606 Income tax payable 157,05756,5657,795 Deferred consideration in connection with business acquisitions-current 28,02727,8633,840 Convertible Senior Notes-current 20,19120,0902,768 Dividends payable -347,40347,873 Long-term borrowings, current portion 1,938,3851,939,245267,235 Short-term borrowings 2,365,535675,00093,017 Total current liabilities 6,398,5324,903,340675,697 Deferred consideration in connection with business acquisitions-non current 65,69465,3109,000 Lease liabilities 115,10592,33812,725 Deferred tax liabilities 241,915254,53035,075 Long-term borrowings -3,227445 Other non-current liabilities 129,051143,55219,782 Total liabilities 6,950,2975,462,297752,724 Shareholder's equity (ii) 11,432,67311,265,5061,552,428 Total liabilities and shareholder's equity 18,382,97016,727,8032,305,152 (ii): As of March 31, 2025, the number of ordinary shares outstanding was 321,338,936. Hello Group Inc. Unaudited Condensed Consolidated Statement of Cash Flows (All amounts in thousands, except share and per share data)Three monthsEnded March 31202420252025RMBRMBUS$ Cash flows from operating activities:Net income 5,184358,48949,401 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation of property and equipment 14,31012,3911,708 Amortization of intangible assets 1,2796,191853 Share-based compensation 54,67040,8605,631 Share of income on equity method investments (14,318)(39,731)(5,475) Returns on investments -50870 Loss on long-term investments 9,245-- Gain or loss on disposal of property and equipment 258(102)(14) Provision of loss on receivable and other assets 1,7765,405745 Changes in operating assets and liabilities:Accounts receivable 10,980(19,144)(2,638) Prepaid expenses and other current assets (9,677)11,3751,568 Rental deposits (802)(110)(15) Deferred tax assets (2,498)34047 Other non-current assets (7,597)35,0464,829 Accounts payable (17,454)(13,543)(1,866) Income tax payable 6,036(100,979)(13,915) Deferred revenue 16,6749,0351,245 Accrued expenses and other current liabilities (56,800)(70,983)(9,782) Deferred tax liabilities 365,01112,7131,752 Other non-current liabilities 23,893(8,040)(1,108) Net cash provided by operating activities 400,170239,72133,036 Cash flows from investing activities:Purchase of property and equipment (44,176)(27,814)(3,833) Payment for business acquisition -(194,390)(26,788) Cash received on maturity of short-term deposits 300,0001,107,245152,582 Purchase of long-term deposits (718,860)-- Cash received on maturity of long-term deposits 718,860150,00020,671 Cash received from sales of long-term investment 2,000-- Loan to a third-party company -(27,478)(3,787) Other investing activities 38519226 Net cash provided by investing activities 258,2091,007,755138,871 Cash flows from financing activities:Proceeds from exercise of share options 112- Repurchase of ordinary shares (112,261)(201,529)(27,771) Proceeds from short-term borrowings 1,331,635-- Repayment of short-term borrowings (215)(1,690,535)(232,962) Repayment of long-term borrowings -(395)(54) Net cash provided (used in) by financing activities 1,219,170(1,892,457)(260,787) Effect of exchange rate changes 20,814(25,685)(3,541) Net increase (decrease) in cash and cash equivalents 1,898,363(670,666)(92,421) Cash, cash equivalents and restricted cash at the beginning of period 8,282,9129,642,4211,328,761 Cash, cash equivalents and restricted cash at the end of period 10,181,2758,971,7551,236,340 Hello Group Inc. Reconciliation of Non-GAAP financial measures to comparable GAAP measures (All amounts in thousands, except per share data)1. Reconciliation of Non-GAAP cost and operating expenses, income from operations, and net income to comparable GAAP monthsThree monthsThree months Ended March 31, 2024Ended March 31, 2025Ended March 31, 2025GAAP Share-basedcompensation Non-GAAPGAAP Amortization ofintangible assetsfrom businessacquisitions Share-basedcompensation Non-GAAPGAAP Amortization ofintangible assetsfrom businessacquisitions Share-basedcompensation Non-GAAP RMB RMB RMB RMB RMB RMB RMB US$ US$ US$ US$ Cost of revenues (1,503,008) 1,882 (1,501,126)(1,569,074) 1,263 1,774 (1,566,037)(216,224) 174 244 (215,806) Research and development (192,191) 8,786 (183,405)(195,769) 859 9,060 (185,850)(26,978) 118 1,249 (25,611) Sales and marketing (293,431) 6,117 (287,314)(329,178) 2,790 4,311 (322,077)(45,362) 384 594 (44,384) General and administrative (131,381) 37,885 (93,496)(140,511) - 25,715 (114,796)(19,363) - 3,544 (15,819) Cost and operating expenses (2,120,011) 54,670 (2,065,341)(2,234,532) 4,912 40,860 (2,188,760)(307,927) 676 5,631 (301,620) Income from operations 460,315 54,670 514,985299,485 4,912 40,860 345,25741,270 676 5,631 47,577 Net income attributable to Hello Group Inc. 5,184 54,670 59,854357,994 4,912 40,860 403,76649,333 676 5,631 55,640 View original content: SOURCE Hello Group Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
24 minutes ago
- Washington Post
NATO set to approve new military purchases as part of a major defense spending hike
BRUSSELS — NATO defense ministers are set Thursday to approve plans to buy more weapons and military equipment to better defend Europe, the Arctic and the North Atlantic, as part of a U.S. push to ramp up security spending . The 'capability targets' lay out plans for each of the 32 nations to purchase priority equipment like air and missile defense systems, artillery, ammunition, drones and 'strategic enablers' such as air-to-air refueling, heavy air transport and logistics.
Yahoo
26 minutes ago
- Yahoo
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ('Alvotech'), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Use of trademarksKeytruda® is a registered trademark of Merck Sharp & Dohme Corp. Sources[1] Accessed on June 4, 2025. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information visit Alvotech's investor portal, and website or follow Alvotech on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to develop or co-develop future products, including the proposed biosimilar to Keytruda®; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. About Dr. Reddy's Laboratories Ltd:Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Over the last 25 years, our Biologics team has developed into a fully integrated organization with robust capabilities in the development, manufacture and commercialization of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across developed as well as emerging markets. We are also ramping up manufacturing capacity to support our global expansion plans. In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner. Our biosimilars business has a key role to play in driving both near-term and long-term growth. For more information, log on to: Dr. Reddy's DisclaimerThis press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words 'may', 'will', 'should', 'expects', 'plans', 'intends', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue' and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the 'Risk Factors' and 'Forward-Looking Statements' sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products. ALVOTECH CONTACTSBenedikt StefanssonVP Investor Relations and Global DR. REDDY'S CONTACTS Priya K Richa Periwal Corporate Communications Head of Investor Relations priyak@ richaperiwal@ in to access your portfolio
